-
-
-
-
-
-
-
PTC Therapeutics (PTCT) Tops Q1 EPS by 43c, provides guidance
-
-
-
-
-
-
-
PTC Therapeutics withdraws Translarna drug application after FDA feedback
-
-
-
-
-
-
-
Sandisk (SNDK) to join S&P 500
-
-
-
-
-
-
-
Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Lowered to $76 at BofA Securities
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Raised to $80 at UBS
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on PTC Therapeutics (PTCT)
-
416,803 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

